Following up last year's deal with Baxter International Inc. for the Janus kinase (JAK) inhibitor pacritinib in myelofibrosis (MF), CTI Biopharma Corp.'s sealed an agreement with Les Laboratoires Servier SA that brings €14 million (US$18.1 million) up front and could be worth as much as €103 million if all milestones are achieved with Pixuvri (pixantrone), conditionally approved in the European Union for aggressive B-cell non-Hodgkin lymphoma (NHL) patients who failed two or three prior lines of therapy.